Lucence Diagnostics
Lucence Taps Omnigen to Distribute Liquid Biopsy Tests in Turkey
The Istanbul-based medical test and device distributor will market Lucence's liquid biopsy tests, including its NGS assay LiquidHallmark, to hospitals and physicians in the region.
Lucence Publishes Clinical Validation of LiquidHallmark Circulating Tumor DNA Test, Expands to RNA
Premium
The firm plans to ramp up US commercialization following the study, while continuing to develop its cell-free RNA diagnostic platform.
Lucence, Veterans' Affairs Health Care System Launch Liquid Biopsy Screening Study
The study will evaluate the feasibility of screening high-risk lung cancer patients with Lucence's LiquidHallmark assay.
Researchers used the amplicon-based LiquidHallmark test to correlate tumor DNA changes with treatment response.
Lucence Presents New Data on Liquid Biopsy for Late-Stage Cancer Monitoring, Treatment Guidance
Premium
The firm shared validation data at ASCO on its LiquidHallmark assay to help guide detection and treatment decisions for late-stage cancers.
Dec 10, 2020
Lucence Obtains CLIA Certification for Palo Alto Lab
Jan 27, 2020
Nov 19, 2019